UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                                     of the
                         SECURITIES EXCHANGE ACT OF 1934
  Date of Report (Date of earliest event reported):July 19,2006(July 18, 2006)

                     CHINA BIOPHARMACEUTICALS HOLDINGS, INC.
                         ------------------------------
             (Exact name of registrant as specified in its charter)



          Delaware                      814-00063                13-2949462
(State or other jurisdiction     (Commission File Number)      (IRS Employer
      of incorporation)                                      Identification No.)

                           Suite 602, China Life Tower
                        16 Chaowai Street, Chaoyang Dist.
                              Beijing, China 100020
                           --------------------------
                    (Address of principal executive offices)

                                 86-10-85251616
                      -------------------------------------
              (Registrant's telephone number, including area code)

       -------------------------------------------------------------------
          (former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

|_| Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))







ITEM 8.01. OTHER EVENTS.

On July 19, 2006 the  registrant  issued a press  release  announcing  that it's
Chairman and Chief Executive  Officer,  Chris Peng Mao, is visiting investors in
the  U.S,  and  his  presentation  can  be  found  under  Investor  Info  at the
registrant's website at www.cbioinc.com.


A copy  of the  press  release  dated  July  19,  2006  is  filed  herewith  and
incorporated herein by reference.





ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.


(d) Exhibits.


99.1 Press Release issued by the Registrant on July 19, 2006.






















                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                China Biopharmaceuticals Holdings, Inc.

                                By:  /s/ Chris Peng Mao
                                -----------------------------
                                    Name:  Chris Peng Mao
                                    Title: Chief Executive Officer

Dated:  July 19, 2006